After some competitors have already submitted, the German biotech company Curevac now also wants to apply for approval of its Covid 19 vaccine candidate – and is planning to penetrate only certain markets for the time being. The German biotech company Curevac will apply for approval of its Covid-19 vaccine candidate in the EU and Latin America. “North America is not yet a market for us. The current administration has pre-ordered and reserved a large number of cans very quickly and from Johnson & Johnson, AstraZeneca and Sanofi-GSK, Moderna and also Biontech / Pfizer,” said CEO Franz-Werner Haas in Tübingen. The approval-relevant clinical phase III study with up to 30,000 participants is to be initiated by the end of 2020, according to Haas.

Recommendation of the Stiko Who should receive the vaccination first

Curevac expects the first results after two to three months. The company is currently waiting to get the green light from the authorities. “We are ready on our own,” said Haas. Other companies are already further. Pfizer, for example, developed a corona vaccine together with the Mainz-based manufacturer Biontech. This is already approved in Great Britain. The Curevac vaccine is also based on the messenger molecule mRNA, which stimulates the formation of a virus protein in the body. This triggers an immune response that is supposed to protect people from the virus. Curevac has already signed a contract with the EU Commission for the purchase of up to 405 million vaccine doses. The company did not say how many cans should go to Germany or Baden-Württemberg. “At Sars-CoV-2 we are in a situation where we have to vaccinate the world. The virus knows no skin color, no religion, no gender and no borders,” said Haas. That is why logistics and the associated robustness of the vaccine are important. “I have to be able to vaccinate quickly and effectively, which is why you have to ensure the logistics.” If you are in countries with a higher temperature and the vaccine has to be brought to remote areas, you need time to move it. “A vaccine that can be stored for a long time at refrigerator temperatures and also remains stable for some time at room temperature has an advantage.”

Biontech, Moderna, Astrazeneca The three top corona vaccines in comparison

The vaccine candidate from Tübingen can be kept for at least three months, even at a temperature of plus five degrees. In addition, CVnCoV, as the liquid is called, remains stable as a ready-to-use vaccine for up to 24 hours at room temperature. Haas described the development of a vaccine against the pandemic in just ten months as a milestone. The risks of errors are present, albeit to a very small extent. “Regardless of technology, the regulatory authorities do not compromise on safety and tolerability.” Curevac is still in the red. Haas does not expect profits until 2022. Haas spoke of around 700 million euros in investment costs related to the development of the vaccine.

Tags: suchen suche search tag anzeigen besucherzahl browser design domain inhalt jahr karpfen konto problem inhalt schalten modellbahn spielemax spiel tag webseite preise werbung

Reichsmarschall Göring hatte eine Märklin Modelleisenbahn >>> read more